See more : Le Saunda Holdings Limited (0738.HK) Income Statement Analysis – Financial Results
Complete financial analysis of NeuroPace, Inc. (NPCE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of NeuroPace, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
- XiNing Special Steel Co., Ltd. (600117.SS) Income Statement Analysis – Financial Results
- Japan Oil Transportation Co., Ltd. (9074.T) Income Statement Analysis – Financial Results
- Ormonde Mining plc (ORQ1.IR) Income Statement Analysis – Financial Results
- Kawasaki Geological Engineering Co., Ltd. (4673.T) Income Statement Analysis – Financial Results
- CStone Pharmaceuticals (2616.HK) Income Statement Analysis – Financial Results
NeuroPace, Inc. (NPCE)
About NeuroPace, Inc.
NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely. It sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. The company was incorporated in 1997 and is headquartered in Mountain View, California.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
---|---|---|---|---|---|
Revenue | 65.42M | 45.52M | 45.18M | 41.14M | 36.97M |
Cost of Revenue | 17.30M | 13.03M | 11.75M | 10.87M | 10.51M |
Gross Profit | 48.12M | 32.49M | 33.44M | 30.27M | 26.46M |
Gross Profit Ratio | 73.56% | 71.38% | 74.00% | 73.59% | 71.58% |
Research & Development | 20.78M | 21.95M | 18.21M | 15.70M | 18.29M |
General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 54.52M | 51.34M | 38.96M | 27.63M | 30.20M |
Other Expenses | 0.00 | -337.00K | -5.38M | 218.00K | 1.28M |
Operating Expenses | 75.30M | 73.29M | 57.17M | 43.32M | 48.50M |
Cost & Expenses | 92.60M | 86.31M | 68.92M | 54.19M | 59.00M |
Interest Income | 3.05M | 1.58M | 448.00K | 41.00K | 261.00K |
Interest Expense | 8.52M | 7.53M | 7.41M | 11.49M | 9.49M |
Depreciation & Amortization | 1.61M | 2.99M | 296.00K | 312.00K | 421.00K |
EBITDA | -22.83M | -36.57M | -28.37M | -12.48M | -20.07M |
EBITDA Ratio | -34.90% | -86.89% | -62.80% | -30.34% | -54.28% |
Operating Income | -27.17M | -40.79M | -23.74M | -13.05M | -22.03M |
Operating Income Ratio | -41.54% | -89.62% | -52.54% | -31.72% | -59.59% |
Total Other Income/Expenses | -5.78M | -6.29M | -12.34M | -11.23M | -7.94M |
Income Before Tax | -32.96M | -47.08M | -36.08M | -24.28M | -29.97M |
Income Before Tax Ratio | -50.38% | -103.43% | -79.85% | -59.02% | -81.07% |
Income Tax Expense | 0.00 | 6.29M | 2.03M | 11.70M | 10.77M |
Net Income | -32.96M | -53.37M | -38.11M | -35.98M | -40.74M |
Net Income Ratio | -50.38% | -117.25% | -84.34% | -87.47% | -110.19% |
EPS | -1.27 | -2.17 | -1.56 | -1.51 | -1.71 |
EPS Diluted | -1.27 | -2.17 | -1.56 | -1.51 | -1.71 |
Weighted Avg Shares Out | 25.85M | 24.59M | 24.45M | 23.83M | 23.83M |
Weighted Avg Shares Out (Dil) | 25.85M | 24.59M | 24.45M | 23.83M | 23.83M |
NeuroPace Continues to Strengthen Management Team
NeuroPace Strengthens Management Team with Two Key Appointments
NeuroPace Announces Participation at Two Upcoming Healthcare Investor Conferences
NeuroPace to Participate in Upcoming Healthcare Conferences in September
NeuroPace: Only For Those With Strong Nerves
NeuroPace (NPCE) Q2 Earnings Beat, '24 Sales View Up
NeuroPace, Inc. (NPCE) Q2 2024 Earnings Call Transcript
NeuroPace to Report Second Quarter 2024 Financial Results on August 13, 2024
NeuroPace, Inc. (NPCE) Q1 2024 Earnings Call Transcript
NeuroPace Reports First Quarter 2024 Financial Results and Provides Corporate Update
Source: https://incomestatements.info
Category: Stock Reports